Assessment
osimertinib
Adjuvant treatment of adult patients with NSCLC stage IB-IIIA with EGFR exon 19 deletion or exon 21 substitution mutation (L858R) after complete tumour resection
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relations